Publication
Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial.
Kohei Shitara, Zev Wainberg, Josep Tabernero, Eric Van Cutsem, Clélia Coutzac, Christelle De La Fouchardière, Jeeyun Lee, Sun Young Rha, Yoon-Koo Kang, Philip Fanning, Alison Forgie, Cherry Mao, Daniel Brickman, Jaume Pons, Athanasios C Tsiatis, Sophia Randolph, Keun-Wook Lee
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Evorpacept blocks the CD47-signal regulatory protein α interaction, enhancing antibody-dependent cellular phagocytosis. In the phase 2 portion of ASPEN-06 (a multicenter, open-label, randomized phase 2/3 study), 127 patients with pretreated, human epidermal growth factor receptor 2…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT05002127registry_reference1.00
Candidate 1
- cancerMalignant Gastric Neoplasmdictionary0.60
Registered trialsNCT05002127
Curated evidence
Evidence citing this paper (0)
Data not yet available